FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

The Food and Drug Administration has officially approved a new option for weight management: a once-daily pill from Eli Lilly called Foundayo. Known scientifically as orforglipron, this medication belongs to a class of drugs called GLP-1s, which work by helping to regulate a person's appetite and food intake. It is specifically authorized for individuals who are overweight or obese and also face weight-related health problems.

In clinical trials, patients taking the highest dose of Foundayo saw notable results. Obese patients without diabetes lost about 11 percent of their body weight, while those with diabetes lost roughly 10 percent. Competitor Novo Nordisk has been quick to point out that its rival Wegovy pill produces a higher average weight loss of 14 percent, but there is an important scientific caveat to keep in mind. The two medications have not yet been tested in head-to-head trials, meaning researchers cannot conclusively determine which drug is actually superior.

Where Foundayo truly stands out is in its everyday convenience. Unlike the Wegovy pill, Foundayo does not need to be taken on an empty stomach. This practical advantage could make it much easier for patients to incorporate the treatment into their daily routines without having to schedule their meals around their medication.